Randomized Phase II Study of Osimertinib +- Chemotherapy in Relapsed EGFR-Mutant NSCLC After Adjuvant Osimertinib (WJOG17523L:ORACLE study)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2026
This article has no abstract
Epistemonikos ID: af2a53b239657803b3a47a04d813e1b837607135
First added on: Aug 10, 2026